http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
F-star Therapeutics Appoints James Sandy as Chief Development Officer
-
Immunocore (IMCR) Announces Positive CHMP Opinion for KIMMTRAK
-
Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
-
Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
-
Immunocore to present at the SVB Leerink Global Healthcare Conference
-
Immunocore to present at the SVB Leerink Global Healthcare Conference
-
Immunocore (IMCR) announces FDA approval of KIMMTRAK for treatment of unresectable or metastatic uveal melanoma
-
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
-
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
-
Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference
-
Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference
-
Immunocore (IMCR) Reports Initial Phase 1 Data of IMC-C103C targeting MAGE-A4
-
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
-
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
-
F-star Therapeutics to Host Virtual R&D Day on December 6, 2021
-
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
-
Immunocore to present at the Jefferies London Healthcare Conference
-
Immunocore to present at the Jefferies London Healthcare Conference
-
Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
-
Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
-
LAVA Therapeutics Expands Management Team with Three Key Appointments
-
Immunocore (IMCR) and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
-
Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
-
Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
-
Immunocore (IMCR) Announces Publication in The New England Journal of Medicine Comparing Phase 3 Data of tebentafusp with Investigator’s Choice
-
Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine
-
Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine
-
Immunocore (IMCR) presents data at ESMO demonstrating reduction in circulating tumor DNA while on tebentafusp is associated with OS in the Phase 2 clinical trial
-
Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall su
-
Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall su
-
Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
-
Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
-
Immunocore to present at upcoming investor conferences
-
Immunocore to present at upcoming investor conferences
-
Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
-
Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
-
Immunocore (IMCR) Announces FDA and EMA accept BLA and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
-
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uve
-
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uve
-
Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meetin
-
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meetin
-
Immunocore to present at upcoming investor conferences
-
Immunocore to present at upcoming investor conferences
-
Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B
-
Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B
-
Immunocore Reports First Quarter 2021 Financial Results
